Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients - Carton, E.; Noe, G.; Huillard, O.; Golmard, L.; Giroux, J.; Cessot, A.; Saidu, N.E.B.; Peyromaure, M.; Zerbib, M.; Narjoz, C.; Guibourdenche, J.; Thomas, A.; et al. (European journal of cancer (1990), 2017)
Keywords: Abiraterone acetate; Aged; Aged, 80 and over; Androgen Antagonists - blood; Androgen Antagonists - pharmacokinetics; Androgen Antagonists - therapeutic use; Androstenes - blood; Androstenes - pharmacokinetics; Androstenes - therapeutic use; Antigens; Cancer; Castration; Chromatography; Confidence intervals; Disease-Free Survival; Drug monitoring; Exposure; Fluorescence; Hematology, Oncology and Palliative Medicine; Humans; Kaplan-Meier Estimate; Liquid chromatography; Logistic Models; Male; Metastases; Metastasis; Metastatic castration-resistant prostate carcinoma; Multivariate analysis; Patients; Pharmacodynamics; Pharmacology; Prospective Studies; Prostate cancer; Prostate-specific antigen; Prostate-Specific Antigen - blood; Prostatic Neoplasms, Castration-Resistant - blood; Prostatic Neoplasms, Castration-Resistant - drug therapy; PSA response; Trough concentration; Drug monitoring; Trough concentration; Metastatic castration-resistant prostate carcinoma; Abiraterone acetate; PSA response